Asset Details
Do you wish to reserve the book?
The association of lipids and novel non-statin lipid-lowering drug target with osteoporosis: evidence from genetic correlations and Mendelian randomization
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The association of lipids and novel non-statin lipid-lowering drug target with osteoporosis: evidence from genetic correlations and Mendelian randomization
Do you wish to request the book?
The association of lipids and novel non-statin lipid-lowering drug target with osteoporosis: evidence from genetic correlations and Mendelian randomization
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The association of lipids and novel non-statin lipid-lowering drug target with osteoporosis: evidence from genetic correlations and Mendelian randomization
2025
Overview
Background
It remains controversial whether lipids affect osteoporosis (OP) or bone mineral density (BMD), and causality has not been established. This study aimed to investigate the genetic associations between lipids, novel non-statin lipid-lowering drug target genes, and OP and BMD.
Methods
Mendelian randomization (MR) method was used to explore the genetic associations between 179 lipid species and OP, BMD. Drug-target MR analysis was used to explore the causal associations between angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C3 (APOC3) inhibitors on BMD.
Results
The IVW results with Bonferroni correction indicated that triglyceride (TG) (51:3) (OR = 1.0029; 95% CI: 1.0014–1.0045;
P
= 0.0002) and TG (56:6) (OR = 1.0021; 95% CI: 1.0008–1.0033;
P
= 0.0011) were associated with an increased risk of OP; TG (51:2) (OR = 0.9543; 95% CI: 0.9148–0.9954;
P
= 0.0298) was associated with decreased BMD; and ANGPTL3 inhibitor (OR = 1.1342; 95% CI: 1.0393–1.2290;
P
= 0.0093) and APOC3 inhibitor (OR = 1.0506; 95% CI: 1.0155–1.0857;
P
= 0.0058) was associated with increased BMD.
Conclusions
MR analysis indicated causal associations between genetically predicted TGs and OP and BMD. Drug-target MR analysis showed that ANGPTL3 and APOC3 have the potential to serve as novel non-statin lipid-lowering drug targets to treat or prevent OP.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Angiopoietin-Like Protein 3 - genetics
/ Angiopoietin-like Proteins - genetics
/ ANGPTL3
/ APOC3
/ Apolipoprotein C-III - antagonists & inhibitors
/ Apolipoprotein C-III - genetics
/ Bias
/ Bones
/ Datasets
/ Density
/ Drug target Mendelian randomization
/ Female
/ Genetic Association Studies - methods
/ Humans
/ Hypolipidemic Agents - therapeutic use
/ Lipids
/ Medicine
/ Mendelian Randomization Analysis - methods
/ Polymorphism, Single Nucleotide
/ Statins
We currently cannot retrieve any items related to this title. Kindly check back at a later time.